Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
Hyung-Joo OhSuk-Chul BaeIn Jae OhCheol-Kyu ParkKyoung-Mi JungDa-Mi KimJung-Won LeeChang Kyun KangIl Yeong ParkYoung-Chul KimPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The addition of nicotinamide with EGFR-TKIs demonstrated potential improvements in PFS and OS, with notable survival benefits for female patients and those who had never smoked (ClinicalTrials.gov Identifier: NCT02416739).
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- end stage renal disease
- clinical trial
- ejection fraction
- study protocol
- newly diagnosed
- double blind
- phase iii
- peritoneal dialysis
- randomized controlled trial
- placebo controlled
- risk assessment
- patient reported outcomes
- climate change
- human health
- open label
- combination therapy